HLA-C and neoplasm: Unlike CAR-T cells, which target surface antigens in a major histocompatibility complex (MHC)-independent manner, TCR-T cells recognize intracellular tumor-derived peptides presented by MHC molecules, enabling them to target a broader range of tumor-associated antigens [8,9,10] (Figure 1).